S&P Futures
4,147.25 +15.00 (+0.36%) Dow Futures
34,131.00 -17.00 (-0.05%) Nasdaq Futures
12,532.00 +117.75 (+0.95%) Russell 2000 Futures
1,969.30 +0.90 (+0.05%) Crude Oil
77.07 +0.66 (+0.86%) Gold
1,970.10 +27.30 (+1.41%)
Vyant Bio, Inc. (VYNT)
After hours:
- Zacks Small Cap Research
VYNT: Predicting Drug Discovery
By John Vandermosten, CFA NASDAQ:VYNT READ THE FULL VYNT RESEARCH REPORT We are initiating coverage of Vyant Bio, Inc. (NASDAQ:VYNT) assigning a valuation of $2.00 per share. Vyant is a drug discovery and development technology company that is focusing on neurodevelopmental and neurodegenerative brain disorders. The company’s strategy for developing new therapies combines the application of
- GlobeNewswire
Vyant Bio Engages LifeSci Capital to Explore Strategic Alternatives
CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it has engaged LifeSci Capital as its financial adv
- GlobeNewswire
Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for Neuroscience
“Targeting specific functional rescue in a Rett patient cortical organoid disease model” CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine lear
